Newly created Mperia gets global rights to CD36 drug-ligands from Universite de Montreal
- R+D and Marketing-Licensing
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.